These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14562121)

  • 21. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
    Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
    Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of G-CSF on the proliferation and differentiation of bcr/abl(+)-CD34+ cells from CML patients].
    Li CY; Meng FY; Sun QX; Fu YB; Jiang QL; Yi ZS; Song LL
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):762-5. PubMed ID: 18457269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
    Melkus M; Bennaceur-Griscelli A; Valogne Y; Flamant S; Chomel JC; Sorel N; Bonnet ML; Deininger MW; Mitjavila-Garcia MT; Turhan AG
    Exp Hematol; 2013 Apr; 41(4):335-45.e3. PubMed ID: 23287417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
    Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
    Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration.
    Petzer AL; Hochenburger E; Haun M; Duba HCh; Grünewald K; Hoflehner E; Sill H; Linkesch W; Gastl G; Gunsilius E
    J Hematother Stem Cell Res; 2002 Apr; 11(2):293-300. PubMed ID: 11983100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of resistance in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Perekhrestenko T; Diachenko M; Sviezhentseva I; Gordienko A; Bilko D
    Georgian Med News; 2015 Mar; (240):43-50. PubMed ID: 25879558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCR/ABL induces multiple abnormalities of cytoskeletal function.
    Salgia R; Li JL; Ewaniuk DS; Pear W; Pisick E; Burky SA; Ernst T; Sattler M; Chen LB; Griffin JD
    J Clin Invest; 1997 Jul; 100(1):46-57. PubMed ID: 9202056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia.
    Krämer A; Löffler H; Bergmann J; Hochhaus A; Hehlmann R
    Leukemia; 2001 Jan; 15(1):62-8. PubMed ID: 11243401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3.
    Holyoake TL; Jiang X; Jorgensen HG; Graham S; Alcorn MJ; Laird C; Eaves AC; Eaves CJ
    Blood; 2001 Feb; 97(3):720-8. PubMed ID: 11157490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
    Demiroglu A; Steer EJ; Heath C; Taylor K; Bentley M; Allen SL; Koduru P; Brody JP; Hawson G; Rodwell R; Doody ML; Carnicero F; Reiter A; Goldman JM; Melo JV; Cross NC
    Blood; 2001 Dec; 98(13):3778-83. PubMed ID: 11739186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukemic burden in subpopulations of CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant or -intolerant patients with chronic myeloid leukemia.
    Van den Berg D; Wessman M; Murray L; Tong J; Chen B; Chen S; Simonetti D; King J; Yamasaki G; DiGiusto R; Gearing D; Reading C
    Blood; 1996 May; 87(10):4348-57. PubMed ID: 8639795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
    Graham SM; Jørgensen HG; Allan E; Pearson C; Alcorn MJ; Richmond L; Holyoake TL
    Blood; 2002 Jan; 99(1):319-25. PubMed ID: 11756187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
    Čokić VP; Mojsilović S; Jauković A; Kraguljac-Kurtović N; Mojsilović S; Šefer D; Mitrović Ajtić O; Milošević V; Bogdanović A; Đikić D; Milenković P; Puri RK
    Blood Cells Mol Dis; 2015 Dec; 55(4):373-81. PubMed ID: 26460262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.
    Holyoake T; Jiang X; Eaves C; Eaves A
    Blood; 1999 Sep; 94(6):2056-64. PubMed ID: 10477735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics.
    Fang B; Zheng C; Liao L; Han Q; Sun Z; Jiang X; Zhao RC
    Blood; 2005 Apr; 105(7):2733-40. PubMed ID: 15591120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
    Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis.
    Fogli M; Carlo-Stella C; Curti A; Ratta M; Tazzari PL; Ragazzi E; Colla S; Santucci AM; Tura S; Lemoli RM
    Exp Hematol; 2000 Jul; 28(7):775-83. PubMed ID: 10907639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors.
    Agarwal R; Doren S; Hicks B; Dunbar CE
    Blood; 1995 Mar; 85(5):1306-12. PubMed ID: 7532038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
    de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
    Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.